New data on REAGILA
was presented at
EPA 2019.
Data from EPAClinical efficacy
Based on data from three positive short-term double-blind studies, cariprazine’s efficacy in acute exacerbation of positive and negative symptoms of schizophrenia was confirmed.1 2 3
At Week 6 cariprazine significantly decreased the PANSS total score compared to placebo.
Paragraph.
View all efficacy dataAtsauces
- Reference title here fringilla eu ante ut malesuada.
- Reference title here placerat erat molestie vitae. In at
porttitor turpis. - Reference title here fringilla eu ante ut malesuada.
Image caption.
REAGILA’s unique mode of action
Cariprazine differs from all available antipsychotics due to its greater affinity for D3 receptors in vivo.
D3 receptors have been theorized to treat hypoactivity symptomology—in particular, cognition, motivation, and reward (1), though EPS side-effects have been seen (2)
Mode of ActionAtsauces title
EXPERT OPINION
PhD. Dr. Stephen Stahl
Adjunct Professor of Psychiatry, University of California San Diego; Honorary Visiting Senior Fellow, University of Cambridge, UK; Chairman, Neuroscience Education Institute (NEI); Chairman, Arbor Scientia Group; Editor-in Chief, CNS Spectrums
Reference
“Cariprazine has unique potent binding for D3 receptors and other unique receptor actions: the low affinities of current antipsychotics for the D3 receptor relative to the very high affinity of dopamine itself for the D3 receptor means that in the living brain, the D3 receptor is not blocked by any antipsychotic other than cariprazine because of the presence of dopamine. That is, because cariprazine is unique among antipsychotics in having a higher potency for the D3 receptor than dopamine itself, the net effect of cariprazine administration is D3 receptor blockade.”
